Get the Stockscreener App
3.81
1.33%
0.05
After Hours:
3.81
Hookipa Pharma Inc stock is traded at $3.81, with a volume of 53,914.
It is up +1.33% in the last 24 hours and down -5.93% over the past month.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
See More
Previous Close:
$3.76
Open:
$3.79
24h Volume:
53,914
Relative Volume:
1.83
Market Cap:
$38.59M
Revenue:
$52.16M
Net Income/Loss:
$-48.60M
P/E Ratio:
-4.1868
EPS:
-0.91
Net Cash Flow:
$-77.48M
1W Performance:
+2.14%
1M Performance:
-5.93%
6M Performance:
-59.04%
1Y Performance:
-17.32%
1-Day Range:
$3.73
$4.0247
1-Week Range:
$3.72
$4.11
52-Week Range:
$3.4145
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
Name
Hookipa Pharma Inc
Sector
Industry
Phone
0114318906360
Address
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-03-20 | Initiated | Truist | Buy |
| Oct-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-19-20 | Resumed | H.C. Wainwright | Buy |
| Sep-27-19 | Initiated | H.C. Wainwright | Buy |
| May-13-19 | Initiated | BofA/Merrill | Buy |
| May-13-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Hookipa Pharma Inc Stock (HOOK) Latest News
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com South Africa
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
HOOKIPA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade - Yahoo Canada Finance
HOOK (HOOKIPA Pharma) Market Cap : $51.06 Mil (As of Aug. 02, 2024) - GuruFocus.com
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 47.1% in July - MarketBeat
Hookipa Pharma (NASDAQ:HOOK) versus AC Immune (NASDAQ:ACIU) Critical Comparison - Defense World
Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00 - Defense World
Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $23.00 at JMP Securities - MarketBeat
Q2 2024 EPS Estimates for Hookipa Pharma Inc (NASDAQ:HOOK) Lifted by Analyst - MarketBeat
Hookipa Pharma Announces Executive Reshuffle and Board Enhancements - TipRanks
Hookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Earn Q2 2024 Earnings of ($1.48) Per Share - Defense World
HOOKIPA Pharma appoints new CEO and CFO, reviews strategy - Investing.com India
HOOKIPA Pharma Appoints Dr. Malte Peters as CEO - citybiz
HOOKIPA Pharma Announces Director Dr. Malte Peters Named CEO And Director Terry Coelho Named Executive Vice President And CFO - Quantisnow
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 - GlobeNewswire
Hookipa Pharma Inc Stock (HOOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):